Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).

Science translational medicine - 8 Aug 2018

Rashid Masturah Bte Mohd Abdul, Toh Tan Boon, Hooi Lissa, Silva Aleidy, Zhang Yanzhou, Tan Pei Fang, Teh Ai Ling, Karnani Neerja, Jha Sudhakar, Ho Chih-Ming, Chng Wee Joo, Ho Dean, Chow Edward Kai-Hua

Abstract excerpt

Multiple myeloma is an incurable hematological malignancy that relies on drug combinations for first and secondary lines of treatment. The inclusion of proteasome inhibitors, such as bortezomib, into these combination regimens has improved median survival. Resistance to bortezomib, however, is a common occurrence that ultimately contributes to treatment failure, and there remains a need to identify improved drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bortezomib
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Drug Synergism

Share to High-Throughput Screening Assays

Share to Mitomycin

Share to Multiple Myeloma

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 6

Source

Identifiers

PMID: 30089632
DOI: 10.1126/scitranslmed.aan0941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).PMID 30089632Read ↗

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomaSemantic proximity Read ↗

Phenotypic response surfaces in pharmacology: Mechanistic and translational perspectives on optimizing drug combination therapies.Semantic proximity Read ↗

Phenotypic response surface-guided pharmacotherapy for personalized combination treatment in complex diseases.Semantic proximity Read ↗

A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML.Semantic proximity Read ↗

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.Semantic proximity Read ↗

Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology.Semantic proximity Read ↗

Multiobjective Optimization Identifies Cancer-Selective Combination TherapiesSemantic proximity Read ↗

Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility AlterationsSemantic proximity Read ↗

Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility AlterationsSemantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cellsSemantic proximity Read ↗

Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.